Chinese Journal of Blood Purification ›› 2018, Vol. 17 ›› Issue (01): 6-8.doi: 10.3969/j.issn.1671-4091.2017.01.002

Previous Articles     Next Articles

Renal anemia and hypoxia inducible factor

  

  • Received:2017-10-27 Revised:2017-11-01 Online:2018-01-12 Published:2018-01-12

Abstract: In anemia associated with renal disease, erythropoiesis is suppressed due to inadequate erythropoietin(EPO) production in kidney, inflammation and iron deficiency. Studies have found that hypoxia inducible factor (HIF) is a key regulator for erythropoiesis and iron metabolism and an effective stimulant for the production of endogenous erythropoietin, through which ferritin level is reduced and iron metabolism is balanced. This review discusses the regulatory effects of HIF on EPO, iron metabolism and bone marrow hematopoiesis, and also introduces the HIF pathway as a novel target for the treatment of renal anemia.

Key words: renal anemia, hypixia inducible factor, hypoxia inducible factor prolyl hydroxylase inhibitor